CHECKPOINT

作品数：720被引量：1395H指数：15
导出分析报告
相关领域：医药卫生自动化与计算机技术更多>>
相关作者：段红刘穆进张彩田志刚景年财更多>>
相关机构：上海大学华中科技大学国防科学技术大学CheckPoint软件技术有限公司更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Cancer Communicationsx
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
《Cancer Communications》2024年第9期1071-1097,共27页Wenyue Sun Shunfeng Hu Xin Wang 
National Natural Science Foundation,Grant/Award Numbers:82270200,82070203,81770210;Key Research and Development Program of Shandong Province,Grant/Award Number:2018CXGC1213;Taishan Scholars Program of Shandong Province,Grant/Award Numbers:tspd20230610,tsqnz20231251;Translational Research Grant of NCRCH,Grant/Award Numbers:2021WWB02,2020ZKMB01;Shandong Provincial Engineering Research Center of Lymphoma;Academic Promotion Programme of Shandong First Medical University,Grant/Award Number:2019QL018;China Postdoctoral Science Foundation,Grant/Award Number:2023M741506;Shandong Provincial Natural Science Foundation,Grant/Award Number:ZR2023QH193。
Immune checkpoints are differentially expressed on various immune cells to regulate immune responses in tumor microenvironment.Tumor cells can activate the immune checkpoint pathway to establish an immunosuppressive t...
关键词：Immune checkpoint hematological malignancies biomarkers therapeutic targets drug resistance 
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors被引量：3
《Cancer Communications》2024年第7期739-760,共22页Yuze Wu Ming Yi Mengke Niu Binghan Zhou Qi Mei Kongming Wu 
National Natural Science Foundation of China,Grant/Award Numbers:82073370,82272794。
Immunotherapy,particularly with immune checkpoint inhibitors,has significantly transformed cancer treatment.Despite its success,many patients struggle to respond adequately or sustain long-lasting clinical improvement...
关键词：IMMUNOTHERAPY RADIOTHERAPY immune checkpoint inhibitor abscopal effect tumor microenvironment 
Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study被引量：1
《Cancer Communications》2024年第6期654-669,共16页Chunyan Lan Huaiwu Lu Lin Zhou Kunlun Liao Junxiu Liu Zhiwen Xie Haixi Liang Guorong Zou Ting Yang Qin Xu Xin Huang 
Research Fund Provincial Enterprise Joint Fund,Grant/Award Number:2021A1515220166;Chinese National Natural Science Foundation project,Grant/Award Number:82273242。
Background:Camrelizumab plus apatinib have demonstrated robust antitumor activity and safety in patients with advanced cervical cancer(CLAP study;NCT03816553).We herein present the updated long-term results of the CLA...
关键词：Cemrelizumab apatinib programmed cell death-1(PD-1) programmed death-ligand 1(PD-L1) tumor mutational burden(TMB) PIK3CA advanced cervical cancer 
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors
《Cancer Communications》2023年第9期1003-1026,共24页Xin-Yu Chen Bin Li Ye Wang Juan Jin Yu Yang Lei-Huan Huang Meng-Di Yang Jian Zhang Bi-Yun Wang Zhi-Ming Shao Ting Ni Sheng-Lin Huang Xi-Chun Hu Zhong-Hua Tao 
National Science and Technology Major Project.Grant Number:2020ZX09201-013。
Background Immune checkpoint inhibitors(ICIs)shed new light on triple-negative breast cancer(TNBC),but only a minority of patients demonstrate response.Therefore,adaptive immune resistance(AIR)needs to be further defi...
关键词：adaptive immune resistance ARID1A CD8+T cell PD-L1 triple-negative breast cancer 
High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway
《Cancer Communications》2023年第5期562-581,共20页Zhaowei Wen Huiying Sun Zhihua Zhang Yannan Zheng Siting Zheng Jianping Bin Yulin Liao Min Shi Rui Zhou Wangjun Liao 
National Natural Science Foundation of China,Grant/Award Numbers:82073303,82103335,82102731;Science and Technology Planning Project of Guangzhou,Grant/Award Number:202201011560;Natural Science Foundation of Guangdong Province of China,Grant/Award Number:2022A1515012418。
Background:Several clinical studies have uncovered a negative correlation between baseline tumor burden and the efficacy of immune checkpoint inhibitor(ICI)treatment.This study aimed to uncover the specific mechanisms...
关键词：CD8^(+)T cell IGFBP2 immune checkpoint inhibitor macrophage PD-L1 STAT3 tumor burden tumor immune microenvironment 
Targeting immune checkpoints:how to use natural killer cells for fighting against solid tumors被引量：3
《Cancer Communications》2023年第2期177-213,共37页Farhoodeh Ghaedrahmati Nafiseh Esmaeil Maryam Abbaspour 
This work was supported by Isfahan University of Medical Sciences,Isfahan,Iran(grant No.140170).
Natural killer(NK)cells are unique innate immune cells that mediate antiviral and anti-tumor responses.Thus,they might hold great potential for cancer immunotherapy.NK cell adoptive immunotherapy in humans has shown m...
关键词：natural killer cell immune checkpoint chimeric antigen receptor-natural killer cell IMMUNOTHERAPY tumor 
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors被引量：6
《Cancer Communications》2023年第2期214-224,共11页Fei Liu ZixianWang Xiaofan Li Zhen Zhang Yue Yang Junquan Chen Dinghua Chen Lingling Wu Xiangyu Liu Sujun Han Fangming Wang Wasilijiang Wahafu Yibo Gao Shancheng Ren Nianzeng Xing Guangyan Cai Xiangmei Chen 
National Key R&D Program of China,Grant/Award Number:2020AAA0109500;National Natural Science Foundation of China,Grant/Award Numbers:82030025,32100631,82003269,82122053;Young Elite Scientists Sponsorship Program by the China Association for Science and Technology,Grant/Award Number:YESS20210056;CAMS Innovation Fund for Medical Sciences,Grant/Award Number:2021-I2M-1-067;Central Research Institute Fund of Chinese Academy of Medical Sciences,Grant/Award Number:2021-PT310-001;Key-Area Research and Development Program of Guangdong Province,Grant/Award Number:2021B0101420005。
With the development and introduction of immune checkpoint inhibitors(ICIs)in cancer patients,immune-related side effects have increasingly attracted attention.However,the risks of immune-related renal toxicity are po...
关键词：immune checkpoint inhibitors acute kidney injury cancer immune therapy side effects 
Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis被引量：6
《Cancer Communications》2022年第9期902-905,共4页Yan Xu Yanjun Song Xiaoyan Liu Yuequan Shi Yingxian Liu Hao Qian Xiaoxing Gao Minjiang Chen Ruili Pan Jing Zhao Wei Zhong Wei Wu Mengzhao Wang 
the Youth Program of National Natural Science Foundation of China(to YX)(82003309);the National Key Research and Development Program of China(to WW)(2016YFC0905102);CAMS Innovation Fund for Medical Sciences(to WW)(CIFMS)(2017-I2M-2-002).
Dear Editor,The application of immune checkpoint inhibitors(ICIs),anti-tumor immunotherapy unleashing the host immune system to eradicate tumor cells,has revolutionized the treatment of various advanced cancers and sh...
关键词：CARDIAC MYOCARDITIS CARDIOVASCULAR 
Epi-immunotherapy for cancers:rationales of epi-drugs in combination with immunotherapy and advances in clinical trials被引量：1
《Cancer Communications》2022年第6期493-516,共24页Yang Xu Ping Li Yang Liu Dijia Xin Wen Lei Aibin Liang Weidong Han Wenbin Qian 
the National Natural Science Foundation of China,Grant/Award Numbers:81830006,82170219,81830004,81800188;the Science Technology Department of Zhejiang Province,Grant/Award Number:2021C03117;the Natural Science Foundation of Zhejiang Province of China,Grant/Award Number:LY21H080005。
Over the last two decades,several epi-drugs,immune checkpoint inhibitors(ICIs)and adoptive cell therapies have received clinical approval for use in certain types of cancer.However,monotherapy with epi-drugs or ICIs h...
关键词：chimeric antigen receptor T cell clinical trial DNA methylation Epi-drug Epiimmunotherapy histone acetylation immune checkpoint.tumor microenvironment vaccine 
The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation被引量：7
《Cancer Communications》2021年第12期1314-1330,共17页Lin Ma Bowen Diao Zhaoqin Huang Bin Wang Jinming Yu Xiangjiao Meng 
The study was funded by the National Natural Science Foundation of China(81972796 and 81972863);Radiation Oncology Innovate Unit,Chinese Academy of Medical Sciences(2019RU071);the Academic Promotion Program of Shandong First Medical University(2019ZL002);the Natural Science Foundation of Shandong(ZR2019MH010 and ZR2020MH289).
Over the past few years,immune checkpoint inhibitors(ICIs)have greatly improved the survival for patients with non-small cell lung cancer(NSCLC)without driver mutations.Compared with wild-type tumors,tumors with epide...
关键词：EFFICACY EGFR mutation immune checkpoint inhibitor non-small cell lung cancer tumor microenvironment 
全选清除导出
共2页<12>
检索报告 对象比较 聚类工具 使用帮助 返回顶部